theMednetRegister
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2024 May 30
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.1.   
ABSTRACT
. .

Related Questions

Would you add immunotherapy to chemotherapy for a patient with metastatic NSCLC, an atypical EGFR mutation, and PD-L1 ≥50% who has progressed on osimertinib?
New comment by Medical Oncologist at CompHealth ( November 15, 2025)
Agree with above; need data with amivantamab alone, or in combo with chemo or lazertinib, in these rare subgroups to guide treatment.
Copyright © 2025 theMednet
All Rights Reserved.